Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

Drugs

Volumn 54, Issue SUPPL.5, 1997, Pages 59-70

  Remme, W J ^a  

^a Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BENAZEPRIL; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; NEUROHORMONE; NORADRENALIN; PERINDOPRIL; RAMIPRIL; VASOCONSTRICTOR AGENT;

CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; REVIEW; VASCULARIZATION;

EID: 0030658903     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700545-00009     Document Type: Review

References (70)

1. Pfeffer MA, Braunwald E, Moyé LA, et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after MI. N Engl J Med 1992; 327: 669-77
2. The SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
3. The SOLVD investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
4. Yusuf S, Pepine CJ, Garces C, et al. Effects of enalapril on MI and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8
5. Xie YW, Shen W, Zhao G, et al. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 1996; 79: 381-7
6. Groves P, Kurz S, Just H, et al. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995; 92: 3421-30
7. Hornig B, Drexler H. Endothelial function and bradykinin in humans. Drugs 1997; 54 Suppl. 5: 42-7
8. Foult JM, Tavolaro O, Antony I, et al. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation 1988; 77: 337-44
9. Remme WJ, Look MP, Bootsma M. Enalaprilat improves coronary flow without affecting systemic hemodynamics. A local tissue effect [abstract]. Circulation 1989; 80: II-558
10. Van den Heuvel AFM, Van der Ent M, Remme WJ. ACE inhibition acutely stimulates sympathetic tone and improves myocardial contractility and coronary flow in coronary artery disease. A bradykinin-related effect? J Am Coll Cardiol 1995; Feb: 337A
11. Mettauer B, Rouleau J-L, Daly P. The effect of captopril on the coronary circulation and myocardial metabolism of patients with coronary artery disease. Postgrad Med J 1986; 62 Suppl. 1: 54-8
12. Daly P, Mettauer B, Rouleau J-L, et al. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation 1985; 71: 317-25
13. Strozzi C, Cocco G, Portaluppi F, et al. Effects of captopril on the physical work capacity of normotensive patients with stable effort angina pectoris. Cardiology 1987; 74: 226-8
14. Jackson NC, Lee PS, Reynolds G, et al. A study of ACE inhibition in angina [abstract no. 338]. Eur Heart J 1987 Sep; 8 Abstract Suppl. 2: 88
15. Rietbrock N, Thurmann P, Kirsen R, et al. Antiischämische Wirksamkeit von Enalapril bei Koronaere Herzkrnkheit. Dtsch Med Wochenschr 1988; 113: 300-2
16. Vogt M, Ulbricht L-J, Motz W. Lack of evidence for antianginal effects of enalapril [abstract]. Circulation 1988; 78 Suppl. II: II-328
17. Gibbs JSR, Crean PA, Mockus L, et al. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 1989; 62: 112-7
18. Klein WW, Khurmi NS, Eber B, et al. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. J Am Coll Cardiol 1990; 16: 948-56
19. Odenthal HJ, Thörmann P, Wiechmann HW, et al. Behandlung der chronisch stabilen Angina pectoris durch Angiotensin-Converting-Enzym Hemmung. Eine randomisierte, placebokontrollierte, doppelblind-cross-over Studie. Z Kardiol 1991; 80: 392-6
20. Van den Heuvel AFM, Van der Ent M, Remme WJ. Enalapril does not affect ischemia during short-term treatment in stable angina pectoris irrespective of its effect on blood pressure [abstract]. J Am Coll Cardiol 1995 Feb; 25 Suppl.: 209A
21. Remme WJ, De Leeuw PW, Bootsma M, et al. Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischaemia in patients with stable angina pectoris. Am J Cardiol 1991; 68: 181-6
22. Remme WJ, Kruijssen HACM, Look MP, et al. Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. J Am Coll Cardiol 1994; 23: 82-91
23. Vita JA, Treasure CB, Young AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acelylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85: 1390-7
24. Nabel EG, Ganz P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988; 77: 43-52
25. Zeiher AM, Drexler H, Wollschlaeger H, et al. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989; 14: 1181-90
26. Perondi R, Saino A, Tio RA, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992; 85: 2004-13
27. Karsch K, Woelker W, Mauser M. Myocardial and coronary effects of captopril during pacing-induced ischaemia in patients with coronary artery disease. Eur Heart J 1990; 11 Suppl. B: 157-61
28. Remme WJ, Bartels GL. Anti-ischaemia effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Eur Heart J 1995; 16 Suppl. 1: 87-95
29. 3H] noradrenaline kinetics in ischaemic heart disease: contrast between unstable anginal syndromes and pacing-induced ischaemia. Br Heart J 1989; 61: 238-47
30. Brilla CG, Weber KT. Reaction and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-7
31. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 5: 1771-9
32. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior MI. N Engl J Med 1988; 319 (2): 80-6
33. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces the regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989; A11 (7): 1325-50
34. Mcdonald KM, Mock J, D'Awia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995; 91: 2043-8
35. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90
36. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-57
37. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J 1989; 30: 219-29
38. Yamada H, Fabris B, Allen AM, et al. Localization of angiotensin-converting enzyme in rat heart. Circ Res 1991; 68: 141-9
39. Vago T, Bevilacqua M, Conci F, et al. Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues. Br J Pharmacol 1992; 107: 821-5
40. Zisman LS, Abraham WT, Meixell GE, et al. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96: 1490-8
41. Megarry SG, Sapsford R, Hall AS, et al. Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction? Drugs 1997; 54 Suppl. 5: 48-58
42. Søgaard P, Gøtzsche K, Ravkilde J, et al. Effects of captopril on ischemia and dysfunction of the left ventricle after MI. Circulation 1993; 87: 1093-9
43. Gibbons GH. Cardioprotective mechanisms of ACE inhibition: the angiotensin II-nitric oxide balance. Drugs 1997; 54 Suppl. 5: 1-11
44. Mombouli J-V. ACE inhibition, endothelial function and coronary artery lesions: role of kinins and nitric oxide. Drugs 1997; 54 Suppl. 5: 12-22
45. Powell JS, Clozel JP, Müller RKM, et al. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension 1991; 18 Suppl. II: 55-1159
46. Farhy RD, Carretero OA, Ho K-L, et al. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993; 72: 1202-10
47. Hanson SR, Powell JS, Dodson T, et al. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 1991; 18 Suppl. II: 1170-6
48. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous intransluminal coronary angioplasty? Circulation 1992; 86: 100-10
49. MARCATOR Investigators. The effect of high dose angiotensin converting enzyme inhibitor on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995; 25: 362-9
50. Shiota N, Okunishi H, Fukamizu A, et al. Activation of two angiotensin generating systems in the balloon-injured artery. FEBS Lett 1993; 323: 239-42
51. Okunishi H, Fukamizu A, Taki S, et al. Angiotensin II antagonist, not ACE inhibitor, prevents neointimal formation on injured canine arteries [abstract]. J Hypertens 1994; 12 Suppl. 3: S132
52. Okunishi H, Oka Y, Shiota N, et al. marked species-difference in the vascular angiotensin II-forming pathways: human versus rodents. Jpn J Pharmacol 1993; 62: 207-10
53. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67
54. Kitazono T, Padgett RC, Armstrong ML, et al. Evidence that angiotensin II is present in human monocytes. Circulation 1995; 91: 715-9
55. Chobanian AV, Haudenschild CC, Nickerson C, et al. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-31
56. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15: S65-S72
57. Rolland PH, Charpiot P, Friggi A, et al. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure,and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993; 71: 22E-27E
58. Finta KM, Fischer MJ, Lee L, et al. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993; 100: 149-56
59. Becker RHA, Weimer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18 Suppl. 2: S110-S115
60. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992; 20: 175-80
61. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258-65
62. Hamsten A, Wallidins G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent MI. Lancet 1987; II: 3-9
63. Hamsten A, Wiman B, deFaire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of MI. N Engl J Med 1985; 313: 1557-63
64. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 22: 390-8
65. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9
66. Swartz SL, Moore TJ. Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. Thromb Haemost 1990; 63: 87-90
67. Someya N, Morotomi, Kodama K, et al. Suppressive effect of captopril on platelet aggregation on essential hypertension. J Cardiovasc Pharmacol 1984; 6: 840-3
68. Young JB. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials. Cardiovasc Drugs Ther 1995; 9: 89-102
69. Hall A, Murray GD. AIRE Extension (AIREX) Study: Authors' reply. Lancet 1997; 350: 367
70. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12: 127-37